Lates News

According to a news flash from Meijing AI, Dongwu Securities released a research report on March 27th, giving a "buy" rating to Wanbangde (002082.SZ). The rating reasons mainly include: 1) The selection of stonepineamine controlled release tablets for the treatment of AD in the national major special project, which is expected to accelerate becoming a first-line drug; 2) WP205 targets the market for amyotrophic lateral sclerosis, with great commercial value potential; 3) Other FDA orphan drug pipelines such as WP103 are expected to gradually realize their value. (Everyday Economic News)